Lucid Diagnostics Inc. LUCD 深 沪
等待开盘 05-15 09:30:00 美东时间
1.02
0.000
0.00%
华盛通- 最 高1.03
- 今 开1.01
- 成交量 182.96万股
- 最 低 0.9533
- 昨 收 1.02
- 总市值 1.99亿
- 52周最高 1.70
- 市盈率 静 --
- 换手率 0.94%
- 52周最低 0.9495
- 委 比 39.21%
- 总股本 1.95亿
- 历史最高 13.52
- 量 比 2.30
- 振 幅 7.52%
- 历史最低 0.6301
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Lucid Diagnostics Q1 Sales $1.256M Miss $1.383M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly sales of $1.256 million which missed the analyst consensus estimate of $1.383 million by 9.18 percent. This is a 57.00 percent increase over sales of $800.000 thousand
05-14 18:02
Lucid Diagnostics Prices Underwritten Registered Direct Offering Of 18M Common Shares At $1.00 Per Share
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the pricing of an
04-23 20:36
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
Texas Instruments To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts change outlook on top names, like AA, SSSS, TXN, HQY, LUCD, RPM, PAR, ASRT. Morgan Stanley raised AA target, Ascendiant raised LUCD.
04-09 22:13
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8.25 to $9.
04-09 18:39
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophagea...
04-02 20:01
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Lucid Diagnostics Files Prospectus To Offer And Sell Shares Of Common Stock Of Up To $25M
-SEC Filing
03-27 05:07
